- AdamTS4 Inhibitor for Respiratory Infection (SJ-20-0025)
- BET Bromodomain Inhibitors (SJ-16-0032)
- Biologically Active Ganoderma Lucidum Compounds and Synthesis of Derivatives and Probes (SJ-19-0035)
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- EZHIP(CXorf67)-PRC2 Interaction and Ependymoma (SJ-17-0030)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- Improved Human Carboxylesterase for Therapy with CPT-11 (SJ-06-0006)
- Method for Improving Learning and Treating Neurological Diseases (SJ-15-0009)
- Method for treating COVID-19 (SJ-20-0035)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Drug Combination for Treating Cytokine Storm Associated With COVID-19 and Other Conditions (SJ-21-0008)
- New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)
- Novel Carboxylesterase Inhibitors (SJ-02-0030)
- P27 Inhibitors for Hearing Regeneration and/or Breast Cancer (SJ-18-0016)
- SARM for Kennedy's Disease (SJ-18-0012)
- SPA70 is a potent antagonist of human pregnane X receptor (PXR Antagonists) (SJ-16-0011)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
- Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
- Transcription Factors for Cochlear Hearing Loss Therapy (SJ-17-0016)
- Treating Cochlear Hearing loss with p27Kip1/Atoh1 Combinations (SJ-13-0019)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
- Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)